Lexi Webster
Reductil, a popular weight loss drug, was banned in Australia in 2010 after studies showed that it could cause major cardiovascular side effects, including heart attacks and strokes. Marketed as an appetite-suppressant, Reductil was prescribed to patients considering obesity surgery or in conjunction with surgery for additional appetite suppression. While some patients found it highly effective, the majority did not feel it helped much, and the weight loss benefits were only marginally better than a placebo. Following the ban, patients were advised to consult their doctors for alternative treatments and to return any remaining pills for a refund.
| Characteristics | Values |
|---|---|
| Status in Australia | Banned since 9 October 2010 |
| Brand Name | Reductil |
| Generic Name | Sibutramine |
| Manufacturer | Abbott |
| Indication | Weight loss |
| Form | Prescription medicine |
| Side Effects | High blood pressure, depression, craving sugary foods, cardiovascular events such as heart attack and stroke |
| Alternative Treatment Options | Gastric banding, bariatric surgery |
Explore related products
What You'll Learn
Reductil was sold in Australia by the pharmaceutical company Abbott
Abbott Australasia ceased the supply of Reductil in Australia from 9 October 2010, following discussions with the Therapeutic Goods Administration (TGA). This decision was informed by the results of the Sibutramine Cardiovascular OUTcome Trial (SCOUT), which showed that the drug was linked to major cardiovascular side effects. The study found that the appetite-suppressant drug increased the risk of cardiac events such as heart attacks and strokes in obese and overweight patients.
The weight-loss benefits of Reductil were found to be only 2.5% more than a placebo, which was described as "disappointing" by the Australian Medical Association vice-president, Steven Hambleton. Despite this, the drug was fairly widely used in Australia, particularly by patients considering obesity surgery or in conjunction with surgery for additional appetite suppression.
Following the announcement of the ban, an Abbott Australia spokeswoman, Jennifer Stevenson, advised patients using the medicine to make an appointment with their doctor to seek advice on alternatives. She also stated that patients who wished to stop treatment before seeing their doctor could do so at any time and that doctors should not issue any new prescriptions for sibutramine.
Improving Organ Donation Rates: Australia's Next Steps
You may want to see also
The drug was banned in Australia in 2010
The weight-loss drug Reductil was banned in Australia in 2010. Reductil is the brand name under which the drug sibutramine was sold in Australia. The drug was banned after a study showed that it could cause people to suffer fatal heart attacks or strokes.
The Sibutramine Cardiovascular OUTcome Trial (SCOUT) study showed that the drug was linked to major cardiovascular side effects. The study, which involved 10,000 patients, found that the weight loss drug was tied to 16% more major cardiovascular side effects. This confirmed preliminary results from the study, which were first released in late 2009 or early 2010, that indicated an increased risk of heart attack and stroke.
Following the study, the Therapeutic Goods Administration (TGA) ruled that the drug should be banned in Australia. On 9 October 2010, Abbott Australasia, the manufacturer of the drug, announced that it would stop distributing sibutramine in Australia. An Abbott Australia spokeswoman, Jennifer Stevenson, advised patients using the drug to make an appointment with their doctor to seek advice on an alternative. She also stated that doctors should not issue any new prescriptions for sibutramine.
The Australian Medical Association vice-president, Steven Hambleton, commented on the study's results, stating that the weight loss benefits of Reductil were only 2.5% more than a placebo, which he described as "disappointing". He added that the risks of the drug outweighed the benefits.
US to Australian Dollars: $1000 Exchange Rate
You may want to see also
Reductil was linked to an increased risk of heart attacks and strokes
Reductil, also known as sibutramine, was a popular prescription weight-loss drug in Australia. It was sold by the pharmaceutical company Abbott and was available in the country from 2001 until it was banned in 2010.
The drug was banned after a major study, the Sibutramine Cardiovascular OUTcome Trial (SCOUT), found that it was linked to an increased risk of heart attacks and strokes. The SCOUT study involved 10,000 patients over six years and showed that the drug was associated with a 16% increase in major cardiovascular side effects.
The Australian Medical Association vice-president, Steven Hambleton, commented on the disappointing results of the study, stating that the weight loss benefits of Reductil were only 2.5% more than a placebo. He also noted that the risks of the drug outweighed its benefits.
Following the release of the SCOUT study results, Abbott announced that it would stop distributing Reductil in Australia. A spokeswoman for the company advised patients who were taking the medication to consult their doctors for alternative options.
While some users found Reductil highly effective for weight loss, others did not experience significant benefits. It is important to note that individual results may vary, and the overall risk of cardiovascular events associated with the use of Reductil was a significant concern. As a result, the decision was made to ban the drug in Australia to protect public health.
Converting Pounds to Australian Dollars: Understanding Exchange Rates
You may want to see also
The weight loss benefits of Reductil were minimal
Reductil, also known as sibutramine, was a prescription weight-loss drug sold in Australia from 2001 until its ban in 2010. The drug was designed to suppress appetite, helping people feel fuller and burn calories faster.
While some people found Reductil highly effective for weight loss, the majority did not feel it helped much. The SCOUT study showed that the weight loss benefits of Reductil were only 2.5% more than a placebo, which experts described as "disappointing".
One reviewer on ProductReview.com.au shared that they "didn't lose any weight" while taking Reductil. Another reviewer mentioned that they gained back the 8kg they had lost while taking the drug.
In addition to its questionable weight loss benefits, Reductil was linked to serious cardiovascular side effects. The SCOUT study found a 16% increase in major cardiovascular events, such as heart attacks and strokes, in obese and overweight patients using sibutramine compared to those managing their weight through exercise and diet alone.
Due to the disappointing weight loss results and the concerning side effects, the risks of taking Reductil were considered to outweigh the benefits. As a result, the drug was banned in Australia in 2010.
Join the Woolworths Team: Your Application Guide
You may want to see also
Reductil was prescribed to patients considering gastric banding
Reductil, also known as sibutramine, was a popular weight-loss drug that was sold in Australia from 2001 until 2010, when it was banned. Reductil was prescribed to patients considering gastric banding to ensure they had explored all available options before undergoing surgery.
Gastric banding is a type of bariatric surgery that involves placing a silicone band around the upper portion of the stomach to reduce stomach capacity and slow the passage of food. This procedure is adjustable and reversible, and it has the lowest complication rate compared to other bariatric procedures. It is considered a purely "restrictive" procedure as it primarily limits how much food can be eaten at one time.
Reductil was often prescribed to patients with obesity who were considering gastric banding. Dr James Ritchie, who performs obesity surgery in Sydney, stated that about half of the patients for bariatric surgery had used Reductil. He also mentioned that while some patients found the drug highly effective, most did not feel it helped significantly.
The decision to prescribe Reductil to patients considering gastric banding was made to ensure that all conservative options had been exhausted before resorting to surgery. Reductil was an appetite suppressant that worked by making people feel fuller and helping to burn calories faster. However, despite its supposed benefits, the drug's effectiveness was questionable, and it carried significant risks.
Following the release of data from the Sibutramine Cardiovascular OUTcome Trial (SCOUT), it was found that Reductil was associated with a 16% increase in major cardiovascular side effects. This led to the Therapeutic Goods Administration's ruling to ban the drug in Australia. The study also showed that the weight loss benefits of Reductil were only marginally better than a placebo, with a disappointing outcome.
Join Target Australia: Your Guide to Applying
You may want to see also
Frequently asked questions
Yes, Reductil has been banned in Australia since 2010.
Reductil was banned in Australia after a study showed that it could cause people to suffer fatal heart attacks or strokes.
Reductil is a prescription medicine indicated for weight loss. It was sold in Australia from 2001 until its ban in 2010.
